Vironova BioAnalytics

Big news🌟: Thrilled to announce Vironova BioAnalytics' acquisition by an investor syndicate, led by Quatre Lab / Columbus Venture Partners with the participation of Accord Investment Partners and Venture Targeter AB. 🌟Following the completion of the acquisition, Vironova BioAnalytics will be renamed and rebranded as 𝐐𝐮𝐓𝐄𝐌. We will still commit to top-notch TEM analyses under GMP. Same excellence, new name—QuTEM is ready to make waves! 🚀 #TEMAnalysis #QualityAssurance #biopharma #vaccines #genetherapy #drugdelivery 

Liposomes have revolutionized drug delivery with their low toxicity, target specificity, and adaptability. As new liposomal drugs continue to enter the market each year, the need for detailed characterization of these drug carriers becomes ever more critical. Regulatory compliance demands rigorous analysis to ensure these systems are optimized for stability, efficacy, and release kinetics. At QuTEM, our cutting-edge TEM analysis provides unparalleled insights into liposomal drug properties. From size distribution and encapsulation efficiency to lamellarity, we deliver the data you need for confident decision-making in formulation and regulatory submissions. Let’s shape the future of precision drug delivery, one liposome at a time! 💊  #PharmaceuticalInnovation #DrugDelivery #Liposomes #TEMAnalysis #QuTEM 

🔬Identify your partially filled subpopulations with TEM! At QuTEM, our Transmission Electron Microscopy (TEM) analysis provides a cutting-edge method to precisely characterize gene therapy vectors. TEM can accurately identify the ratio of overfilled, filled, partially filled, empty particles, and determine the genome length in your subpopulations.    Ensuring the highest product quality at every stage of development and across the product lifecycle is key for the safety and potency of medicinal products. A cornerstone of this process is robust characterization analysis, which provides precise and accurate data about critical quality attributes throughout product development.    With our analysis, you can:   ✔ Pinpoint subpopulations and accurately distinguish between overfilled, filled, and partially filled particles.   ✔ Accurately determine genome length of each subpopulation.   ✔ Detect and analyze product impurities and aggregates effectively.   ✔ Assess particle integrity, including intact and broken particles, doublets, and triplets.     Ready to elevate your gene therapy development? 💡 Let's innovate together and drive progress in gene therapy!   #QuTEM #LifeScience #GeneTherapy #Innovation #AAV   

If you're attending the 6th Annual Gene Therapy for CNS Summit in Boston, make sure attend our CEO Josefina Nilssons presentation at 10 am EST #TODAY! Or find her at the conference to talk about our GMP-certified TEM services, quality control analyses of nanoparticles, or simply to say hello. This year’s summit focuses on breaking barriers in gene therapy for neurological conditions, from novel AAV performance to improving biodistribution and translating these therapies from preclinical models to real-world clinical success. As a company committed to advancing treatments and we’re thrilled to be part of this conversation with leading experts in translational research, R&D, and clinical innovation. #GeneTherapy #Neurology #Innovation #Leadership #TEM #QuTEM

Identify your partially filled subpopulations with TEM!   At QuTEM, our Transmission Electron Microscopy (TEM) analysis🔬 provides a cutting-edge method to precisely characterize gene therapy vectors. From determining vector content to accurately identifying the ratio of overfilled, filled, partially filled, and empty particles, our technology delivers the insights you need to ensure safety and efficacy.   With our analysis, you can:   ✔ Pinpoint subpopulations and accurately distinguish between overfilled, filled, and partially filled particles.  ✔ Accurately determine genome length of each subpopulation.  ✔ Detect and analyze product impurities and aggregates effectively.  ✔ Assess particle integrity, including intact and broken particles, doublets, and triplets.    Ready to elevate your gene therapy development? 💡 Let's innovate together and drive progress in gene therapy!  #QuTEM #LifeScience #GeneTherapy #Innovation #AAV 

Exciting news! QuTEM (formerly Vironova BioAnalytics) will be attending the 6th Annual Gene Therapy for CNS Summit in Boston, this week. If you're onsite make sure to find very own CEO Josefina Nilsson PhD whether you're interested in GMP-certified TEM services, quality control analyses of nanoparticles, or simply want to say hello. This year’s summit focuses on breaking barriers in gene therapy for neurological conditions, from novel AAV performance to improving biodistribution and translating these therapies from preclinical models to real-world clinical success. As a company committed to advancing treatments and we’re thrilled to be part of this conversation with leading experts in translational research, R&D, and clinical innovation. #GeneTherapy #Neurology #Innovation #Leadership #TEM #QuTEM 

🎉 Happy Birthday to QuTEM! 🎉 Today, November 15th, marks a significant milestone for us – our one-year anniversary since being acquired by QUATRE LAB, Venture Targeter (Katalysen Ventures and Andreas Dahlén), and Sam Breuning, and rebranding as QuTEM! In the past 12 months, we’ve been expanding our team, obtaining GMP certifications and manufacturing permits, and validating our 3rd Generation Vector Content and Genome Length Determination (GLD) platform. With all this progress we’ve laid a strong foundation for the future. We would like to thank our investors, clients, partners, and the entire QuTEM team for the amazing work and continued support. Looking ahead, we’re committed to becoming the preferred partner for life science companies, setting the gold standard for safe and effective therapy development with TEM. Together, we are creating something truly impactful in the life sciences. Together we're shaping the future of life sciences with a commitment to impactful innovation. Cheers, to many more years of growth and success ahead! 🚀 

🌍 World Diabetes awareness day, November 14🌍 Diabetes diagnoses have surged nearly 380% from 1988 to 2013, with WHO predicting it will be the 7th leading cause of death by 2030. A dedicated day highlights the urgency of this growing epidemic. 🏃 Preventable with Lifestyle Choices: Type II diabetes can often be prevented through healthy habits. Regular exercise, a balanced diet, and avoiding tobacco play a big role in lowering risk. 📚 Educating Ourselves: Type I and Type II diabetes affect millions, yet many are unaware of the symptoms or the importance of early testing. Join us this World Diabetes Day by wearing the blue circle, getting tested, and sharing knowledge. Together, we can spread awareness and work toward a healthier future! #diabetesawareness #WHO #TEM #QuTEM #health #prevention

🔬 Characterizing Partially Filled subpopulations 🔬𝐖𝐢𝐭𝐡 𝐜𝐫𝐲𝐨𝐠𝐞𝐧𝐢𝐜 𝐓𝐫𝐚𝐧𝐬𝐦𝐢𝐬𝐬𝐢𝐨𝐧 𝐄𝐥𝐞𝐜𝐭𝐫𝐨𝐧 𝐌𝐢𝐜𝐫𝐨𝐬𝐜𝐨𝐩𝐲 (𝐜𝐫𝐲𝐨𝐓𝐄𝐌), we at QuTEM can accurately characterize capsid populations whether empty/full or especially partially filled, and the genome length of each subpopulation. CryoTEM offers insights into transgene incorporation, allowing us to better assess the safety and efficacy of AAV products. In the field of gene therapy, ensuring product safety and potency is paramount. One critical factor that often goes under the radar is the presence of partially filled capsids. These capsids pose unique challenges, as they can carry impurities such as host cell DNA, plasmid DNA, and even fragments of the transgene component. These impurities may cause adverse effects, presenting a significant concern for patient safety. Ultimately, maintaining high-quality standards across all stages of product development and throughout the product lifecycle is essential. By implementing robust characterization analyses and monitoring critical quality attributes, we can enhance the safety, efficacy, and overall success of gene therapies. #GeneTherapy #Biotechnology #CryoTEM #CapsidCharacterization #DrugDevelopment #TEM

Turns out, stars come in all sizes. We've found nano-stars under the microscope, but nothing shines quite like the star that is Mathieu Colomb-Delsuc! Today is his birthday and for the last 10 years, Mathieu, has been lighting up our workplace galaxy—bringing cosmic levels of dedication, a gravitational pull that keeps us all grounded, and the kind of energy that makes the day stellar. ⭐ Thank you, Mathieu for being our very own supernova of hard work and positivity. Here’s to many more years of orbiting success together! 🚀🌌 #EmployeeAppreciation #10YearsStrong #ShiningStar #TeamSuccess #CelebratingExcellence #TEM